GET DAILY SIGNALSWhy Is Agios Pharmaceuticals (AGIO) Stock Down -16.73% Today?
Key Takeaways
- Agios Pharmaceuticals (AGIO) fell roughly 16.73% in Friday's session after the U.S. FDA extended its review of the company's lead drug for a key label expansion.
- The primary catalyst was a three-month FDA review extension for Pyrukynd (mitapivat) in sickle cell disease, pushing the target action date to February 1, 2027.
- The agency classified newly submitted information as a "major amendment," signaling a longer regulatory path than investors had anticipated.
- The decline comes despite broadly positive analyst sentiment, with several firms maintaining Buy ratings and price targets well above current levels.
- Traders are now watching the company's third-quarter earnings report, scheduled for November 5, 2026, for updated commercial guidance.
- For more detail on valuation and outlook, explore Price Targets, Earnings, and Forecast pages.
- To see how AI-driven strategies are positioning around stocks like this, explore Trending AI Robots.
Opening Summary
Agios Pharmaceuticals, Inc. (AGIO), a commercial-stage biopharmaceutical company focused on rare-disease medicines for conditions of cellular metabolism, saw its shares drop sharply on Friday. The stock traded near $31.00 intraday, down approximately 16.73% from the prior session's close of $37.23. The move followed the company's disclosure that the U.S. Food and Drug Administration (FDA) would take additional time to complete its review of a supplemental New Drug Application (sNDA) for Agios's lead product, Pyrukynd.
Catalyst Breakdown: FDA Extends Review of Pyrukynd Label Expansion
The dominant driver behind the sell-off was a regulatory setback. Agios announced that the FDA issued a three-month extension of the review period for its marketing application seeking a label expansion of Pyrukynd (mitapivat) to treat sickle cell disease, a rare, inherited blood disorder. The agency indicated that information the company submitted in response to an FDA request constitutes a "major amendment" to the application, pushing the new target action date to February 1, 2027.
The extension is notable because the FDA had previously granted priority review to the application in July, a designation that typically reflects a faster evaluation timeline. Investors had been pricing in a comparatively near-term approval decision, and the shift to a longer review window disappointed those expectations, triggering the sharp price decline. The information request was tied to the agency's assessment of whether a Risk Evaluation and Mitigation Strategy (REMS) is required for mitapivat in sickle cell disease.
Pyrukynd is already approved in the U.S. for adults with pyruvate kinase deficiency and thalassemia. Sickle cell disease represented a major commercial expansion opportunity, and the delayed decision introduces fresh uncertainty around the timing of potential incremental revenue.
Market Context and Trading Activity
The decline was driven by a company-specific regulatory event rather than broader market weakness, meaning the stock's move diverged from the wider biotech sector. Trading volume was elevated as investors repriced the impact of the delayed FDA decision. The gap-down open and sustained selling pressure reflect a classic negative market reaction to an unexpected regulatory update.
The move also underscores how sensitive small- and mid-cap biopharmaceutical names are to binary regulatory catalysts. While Agios has maintained a strong analyst following, with a consensus leaning toward Buy, a single development-path change can outweigh longer-term fundamental arguments in the near term.
What Comes Next for AGIO
Attention now turns to Agios's third-quarter 2026 earnings report, scheduled for November 5, 2026. Investors will look for updates on Pyrukynd's commercial trajectory in its currently approved indications, as well as any additional commentary from management on the sickle cell disease regulatory timeline and the REMS review.
Beyond earnings, the key milestones are the FDA's continued review of the sNDA and any clarity on the new February 2027 action date. Risks include the possibility of further regulatory requests, competition in the sickle cell disease space, and the company's ongoing path to profitability amid significant net losses. The delayed decision introduces a longer period of uncertainty that could keep near-term sentiment cautious even if the longer-term analyst outlook remains constructive.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of these bots across thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Only the strongest performers are featured in the Trending AI Robots section, giving traders a focused view of active strategies. Explore the page to see how AI-powered approaches are navigating today's markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AGIO in +3.45% Uptrend, rising for three consecutive days on October 28, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AGIO advanced for three days, in 229 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for AGIO crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for AGIO moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 26 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 67 cases where AGIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AGIO as a result. In 76 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for AGIO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 36 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
AGIO moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
AGIO broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AGIO entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.743) is normal, around the industry mean (3.104). P/E Ratio (-4.272) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (19.685) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. AGIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics
Industry Biotechnology
Advertisement